Veradermics MANE
NYSE MANE
$148.63 +4.88 (+3.39%)
At close: Nov 10, 2026 · 4:00 PM EST

Veradermics (MANE) Cash from Financing Activities (2025 - 2026)

Updated

Veradermics (MANE) reported Cash from Financing Activities of $442.7 million for Q2 2026, compared with $129,000 a year earlier and up 64.5% from the prior quarter.

Analysis

Veradermics (MANE) Cash from Financing Activities (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Veradermics' Cash from Financing Activities came in at $720.36 million; for FY2025, it was $159.14 million, up 163.1% from FY2024.

  • By year, Cash from Financing Activities came in at $60.48 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -7.22 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -8.53 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 6.82 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -2.43 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 6.63 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -4.39 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -1.53 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -2.51 Bn
10 Veradermics 822.06 Mn -1.33 Bn - 1.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1.33 Mn
Jun 30, 2026 442.70 Mn
Mar 31, 2026 269.11 Mn
Dec 31, 2025 149.51 Mn
Sep 30, 2025 1.08 Mn
Jun 30, 2025 129,000.00
Mar 31, 2025 8.42 Mn
API Access

Veradermics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=MANE&period=max&api_key=YOUR_API_KEY